** Shares in Novo Nordisk rise around 2% after its controlling shareholder said on Saturday it had fulfilled regulatory conditions to acquire Catalent in the U.S.
** The deal involves the sale of three Catalent manufacturing sites to Novo Nordisk
** The conversion of the Catalent sites will provide Novo with much more filling capacity than is currently anticipated, J.P.Morgan analysts say
** This will allow Novo to not only ramp the U.S. supply of Wegovy faster from 2026, but also the global supply of Ozempic and the supply of Wegovy excluding the U.S. also from 2026, the broker adds
** Separately, Novo Nordisk said it plans to invest 8.5 billion Danish crowns ($1.20 billion) in a new plant in Denmark
** Novo Nordisk shares top the Copenhagen blue chip index
($1 = 7.0971 Danish crowns)
(Reporting by Boleslaw Lasocki)
((boleslaw.lasocki@thomsonreuters.com; +48 58 769 66 00;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.